The phrase "assessment at visit" is correct and usable in written English.
It can be used in contexts related to healthcare or evaluations where an assessment is conducted during a visit, such as a medical appointment or consultation.
Example: "The doctor will conduct a thorough assessment at visit to determine the patient's condition and treatment plan."
Alternatives: "evaluation during visit" or "check-up at appointment".
All patients completed the CRQ-SAS (follow-up administration), SGRQ-C, and mMRC (patient-completed form) and spirometry assessment at Visit 2. A second 6-MWT was also completed in the subset of sites.
The duration of the study was 5 months, during which time the patients attended the center for assessment at visit 2 (day 3 ± 1), visit 3 (day 8 ± 1), visit 4 (day 14 ± 2), visit 5 (weeks 12 13), visit 6 (weeks 16 17), and visit 7 (weeks 20 21).
Participants who met initial eligibility criteria were randomised at this stage, prior to final eligibility assessment at visit 2. At visit 2, designated the baseline visit, the Qoltech asthma control questionnaire (ACQ) 34 was administered and PEFvar (PEF variability measured as the amplitude as a percentage of the mean) calculated.
The effectiveness of the therapy was assessed on the basis of objective symptoms (mucosal hyperemia and swelling of tonsils; investigator assessment at visits 1 and 2), subjective symptoms (achiness/fatigue, sore throat, pain in the extremities, headache, loss of appetite, cough, and hoarseness; parents rated and recorded the subjective symptoms in patient diaries) and responder rate.
Post hoc multivariate analyses of variance (MANOVA) were conducted with the four groups as between-subject factor, and with the repeated assessment at Visits 1, 2 and 3 as within-subject factor.
Additional safety assessments at Visit 3 included vital signs (resting blood pressure and pulse), VA, and slit-lamp examination.
Changes between baseline and day-60 visit (no assessment at final visit was foreseen) were negligible for all treatments and in both eyes.
Patients underwent screening and baseline assessments at visits 1 and 2 and those who met eligibility criteria were randomized 1 1 to the addition of rasagiline 1 mg/day or matching placebo according to a computer-generated randomization list.
Suggested assessments at visits included, but were not limited to: testosterone levels (total, free, and bioavailable), PSA, anthropometric measures, vital signs, cholesterol panel, hematology, and fasting glucose measures, and were measured according to the physician's usual practice, including the measurement of free testosterone.
A total of 1,110 children completed at least one cognitive assessment at a visit in mid-childhood (mean age, 8.0 years; 80% 7 or 8 years at assessment).
Both patients and clinicians then completed the same set of post-interview assessments as at visit 2. The 2-COM induced a stable improvement of patient-reported quality of patient-doctor communication (B = 0.33, P= 0.031), and induced changes in management immediately after the intervention.
